Insider Selling: Cellebrite DI (NASDAQ:CLBT) Insider Sells 3,049 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) insider Holly Windham sold 3,049 shares of the business’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $10.65, for a total transaction of $32,471.85. Following the completion of the transaction, the insider owned 92,279 shares in the company, valued at approximately $982,771.35. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT opened at $11.16 on Thursday. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 1.35 and a beta of 1.06. The firm’s 50-day simple moving average is $11.57 and its 200 day simple moving average is $13.15. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.39.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CLBT. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. DA Davidson reissued a “buy” rating and issued a $15.00 price objective on shares of Cellebrite DI in a research report on Tuesday, September 15th. Needham & Company LLC upped their target price on Cellebrite DI from $12.50 to $14.00 and gave the stock a “buy” rating in a report on Thursday, November 12th. JPMorgan Chase & Co. cut their price target on shares of Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, November 13th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.75.

Check Out Our Latest Stock Report on CLBT

Hedge Funds Weigh In On Cellebrite DI

A number of large investors have recently modified their holdings of the business. Light Street Capital Management LLC raised its position in shares of Cellebrite DI by 104.8% in the second quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company’s stock valued at $19,166,000 after buying an additional 671,830 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Cellebrite DI during the first quarter worth about $2,134,000. Nine Ten Capital Management LLC boosted its position in Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after acquiring an additional 682,933 shares during the period. Wellington Management Group LLP grew its holdings in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after acquiring an additional 1,475,579 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after acquiring an additional 365,700 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Featured Articles

Insider Buying and Selling by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.